DOCSLIB.ORG

Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus BASIC RESEARCH www.jasn.org Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus Fre´de´ ric Jean-Alphonse,* Sanja Perkovska,* Marie-Ce´line Frantz,† Thierry Durroux,* Catherine Me´jean,* Denis Morin,* Ste´phanie Loison,† Dominique Bonnet,† Marcel Hibert,† Bernard Mouillac,* and Christiane Mendre* *CNRS UMR 5203, Institut de Ge´nomique fonctionnelle, INSERM U661, and Universite´ Montpellier I and II, Montpellier, France; and †CNRS UMR 7175, Institut Gilbert Laustriat, and Universite´ Louis Pasteur, Illkirch, France ABSTRACT X-linked congenital nephrogenic diabetes insipidus (cNDI) results from inactivating mutations of the human arginine vasopressin (AVP) V2 receptor (hV2R). Most of these mutations lead to intracellular retention of the hV2R, preventing its interaction with AVP and thereby limiting water reabsorption and concentration of urine. Because the majority of cNDI-hV2Rs exhibit protein misfolding, molecular chaperones hold promise as therapeutic agents; therefore, we sought to identify pharmacochaperones for hV2R that also acted as agonists. Here, we describe high-affinity nonpeptide compounds that promoted maturation and membrane rescue of L44P, A294P, and R337X cNDI mutants and restored a functional AVP-dependent cAMP signal. Contrary to pharmacochaperone antagonists, these compounds directly activated a cAMP signal upon binding to several cNDI mutants. In addition, these molecules displayed original functionally selective properties (biased agonism) toward the hV2R, being unable to recruit arrestin, trigger receptor internaliza- tion, or stimulate mitogen-activated protein kinases. These characteristics make these hV2R agonist phar- macochaperones promising therapeutic candidates for cNDI. J Am Soc Nephrol 20: 2190–2203, 2009. doi: 10.1681/ASN.2008121289 The antidiuretic hormone arginine-vasopressin congenital nephrogenic diabetes insipidus (cNDI), (AVP) is crucial for osmoregulation, cardiovascular a rare disease characterized by the kidney’s inability control, and water homeostasis. The human AVP to concentrate urine despite normal or elevated 4 V2 receptor (hV2R), localized in the principal cells plasma concentrations of AVP. More than 200 dif- of the kidney collecting duct, mediates AVP antidi- ferent mutations have been described and are re- uretic effect and therefore helps in maintaining sponsible for polyuria, a main consequence of the physiologic plasma osmolality, blood volume, and disease. Most of the mutant receptors (cNDI- arterial pressure. Binding of AVP to hV2R first trig- hV2Rs), trapped in the endoplasmic reticulum gers a cAMP signal through activation of the G pro- ␣ tein s (Gs) subunit and adenylyl cyclase (AC). Received December 22, 2008. Accepted June 30, 2009. Then, the cAMP-activated protein kinase A phos- Published online ahead of print. Publication date available at phorylates aquaporin 2 water channels, resulting in www.jasn.org. their insertion into the luminal membrane of prin- F.J.-A., S.P., and M.-C.F. contributed equally to this work. cipal cells and finally to water reabsorption.1 AVP Correspondence: Dr. Christiane Mendre or Bernard Mouillac, IGF, binding to hV2R also induces arrestin recruitment, 141 rue de la Cardonille, 34094 Montpellier Cedex, France. Phone: receptor internalization,2 and mitogen-activated ϩ33-467-142-984/467-142-922; Fax: ϩ33-467-542-432; E-mail: protein kinase (MAPK) activation.3 [email protected] or [email protected] ᮊ Mutations in the hV2R gene lead to the X-linked Copyright 2009 by the American Society of Nephrology 2190 ISSN : 1046-6673/2010-2190 J Am Soc Nephrol 20: 2190–2203, 2009 www.jasn.org BASIC RESEARCH A (ER), cannot reach the cell surface and interact with AVP.5 cNDI is thus referred as a conformational or protein-misfold- ing disease.6 Various chaperones,7 either chemical (cellular osmolytes such as glycerol or DMSO) or pharmacologic (specific li- gands),8,9 are promising therapeutic agents for future clinical treatment of protein-misfolding disorders. Because a majority of cNDI-hV2Rs are misfolded and many ligands are available for hV2R, the pharmacochaperone-based strategy is of partic- B ular interest for cNDI. Considering an efficient therapy for this disease, the ideal drug should combine pharmacochaperone properties together with hV2R agonist and noninternalizing activities, for stimulating AC and maintaining a long-lasting cAMP signal. This would classify such a molecule as a biased agonist or functionally selective compound.10 Small nonpeptide AVP antagonists (commonly named vaptans)—such as the hV2R-selective antagonists SR121463 (satavaptan), VPA985 (lixivaptan),11 OPC41061 (tolpavtan), Figure 1. Structure of the three MCF nonpeptide compounds and OPC31260 (mozavaptan)12; the V receptor (V R) an- and snake-like plot of the hV R. (A) Chemical structures of 1a 1a 2 tagonist SR49059 (relcovaptan); and the nonselective V R/ MCF14, MCF18, and MCF57. (B) L44P, L59P, Y128S, A294P, and 1a 13 R337X cNDI mutants of the hV R used in the study. V2R antagonist YM087 (conivaptan) —were demonstrated 2 to promote adequate maturation and cell surface rescue of cNDI-hV2Rs, with restoration of their capacity to initiate a cell A B CD Figure 2. Binding profiles of AVP and MCF compounds for human AVP/OT receptor subtypes expressed in tsA201 cells. Competition experiments using [3H]AVP as radioligand on tsA201 transfected cells were done as described in the Concise Methods section and in 3 f F the legend to Table 1. (A through D) [ H]AVP competition experiments to each human c-myc–tagged AVP/OT receptors ( ,V2; ,V1a; ‚ E ,V1b; , OTR) were performed using increasing concentrations of unlabeled ligand: AVP (A), MCF14 (B), MCF18 (C), and MCF57 (D). Specific binding was expressed as percentage of the specific binding measured in the presence of vehicle only. Results illustrated correspond to an experiment representative of three independent experiments, each performed in duplicate. J Am Soc Nephrol 20: 2190–2203, 2009 V2R Biased Agonist Pharmacochaperones 2191 BASIC RESEARCH www.jasn.org Table 1. Affinity of the MCF nonpeptide compounds for the human AVP/OT receptor subtypes Receptors Compound c-myc-hV2R c-myc-hV1aR c-myc-hV1bR c-myc-hOTR Ki nM V2-SI Ki nM V2-SI Ki nM V2-SI Ki nM V2-SI AVP 5.3 Ϯ 0.5 1.0 1.1 Ϯ 0.2 0.2 1.4 Ϯ 0.3 0.3 6.3 Ϯ 0.7 1.2 MCF14 6.2 Ϯ 0.8 1.0 19.0 Ϯ 3.0 3.1 Ͼ1000 Ͼ100 37.0 Ϯ 8.0 6.0 MCF18 20.0 Ϯ 3.0 1.0 106.0 Ϯ 10.0 5.3 Ͼ1000 Ͼ100 31.0 Ϯ 7.0 1.5 MCF57 18.0 Ϯ 3.0 1.0 122.0 Ϯ 34.0 6.8 Ͼ1000 Ͼ100 214.0 Ϯ 55.0 12.0 Binding assays were performed as described in the Concise Methods section and are illustrated in Figure 2. ͓3H͔AVP binding was measured on whole tsA201 cells transfected with c-myc-hV2R, c-myc-hV1aR, c-myc-hV1bR, or c-myc-hOTR subtypes and displaced using increasing concentrations of AVP, MCF14, MCF18, ͓3 ͔ or MCF57. Inhibition constants (Ki in nM) were determined from the competition experiments performed using H AVP concentrations around Kd for the Ϯ ϭ various receptors (i.e., 1.5 nM). Data are means SEM of three distinct experiments each done in duplicate. V2-SI (normalized selectivity index) Ki MCF or ͓3 ͔ Ϯ Ϯ AVP for VxR/Ki MCF or AVP for V2R. The Kd for H AVP, calculated from saturation binding assays done on whole tsA201 cells were 2.20 0.40, 0.76 0.08, Ϯ Ϯ 0.85 0.04, and 3.10 0.30 nM for c-myc-hV2R, c-myc-hV1aR, c-myc-hV1bR, and c-myc-hOTR, respectively. Table 2. Agonist properties of the nonpeptide compounds on c-myc-hV2R–stimulated AC activity cAMP Accumulation Compound EC50 (nM) Emax (%) AVP 0.05 Ϯ 0.01 100 MCF14 4.00 Ϯ 2.00 96 Ϯ 5 MCF18 7.00 Ϯ 1.00 95 Ϯ 3 MCF57 6.00 Ϯ 2.00 103 Ϯ 7 Accumulation of cAMP was performed as described in the Concise Methods section and supplemental information, using an homogeneous time-resolved fluorescence-fluorescence resonance energy transfer technology developed by CisBio Int. TsA201 cells transfected with the myc-hV2R were stimulated for 30 min with increasing concentrations of AVP, MCF14, MCF18, or MCF57 in Figure 3. Determination of agonist properties of the nonpeptide the presence of 0.1 mM of the phosphodiesterase inhibitor RO 201724. The cAMP accumulation was expressed as the mean Ϯ SEM of cAMP compounds for the c-myc–tagged hV2R using cAMP accumula- concentration (nM) and reported as percentage of the maximal AVP response Ϯ tion as a readout. The tsA201 cells transfected with the c-myc- (Emax). EC50s in the table are the mean SEM from three distinct Њ hV2R were incubated for 30 min at 37 C in a cAMP buffer con- experiments performed in triplicate and described in the legend to Figure 3. taining 0.1 mM RO 201724 with or without increasing amounts of AVP (F), MCF57 (E), MCF14 (‚), or MCF18 (f). As described in RESULTS the Concise Methods section, cAMP accumulation was evaluated using the Cisbio International Dynamic 2 kit based on fluores- Nonpeptide Compounds Have a High Affinity for hV2R cence resonance energy transfer measurements. Basal cAMP ac- and Induce Receptor-Dependent cAMP Production cumulation values were subtracted from values obtained with To develop ligands exhibiting both hV R agonist properties AVP or MCFs. Data are means Ϯ SEM of cAMP concentration 2 and pharmacochaperone effects on cNDI-hV Rs, we used the (nM). The figure illustrates an experiment representative of three 2 distinct experiments, each performed in triplicate. Otsuka OPC23h and the Wyeth-Ayerst WAY-VNA-932 non- peptide hV2R agonist molecules as lead compounds. New mol- ecules derived from these antidiuretics were synthesized for response upon AVP binding.
Load more

Recommended publications
  • Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
    J Pharmacol Sci 124, 1 – 6 (2014) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Current Perspective Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure Yasukatsu Izumi1,*, Katsuyuki Miura2, and Hiroshi Iwao1 1Department of Pharmacology, 2Applied Pharmacology and Therapeutics, Osaka City University Medical School, Osaka 545-8585, Japan Received October 2, 2013; Accepted November 17, 2013 Abstract. Arginine vasopressin (AVP) is a 9-amino acid peptide that is secreted from the posterior pituitary in response to high plasma osmolality and hypotension. AVP has important roles in circulatory and water homoeostasis, which are mediated by oxytocin receptors and by AVP receptor subtypes: V1a (mainly vascular), V1b (pituitary), and V2 (renal). Vaptans are orally and intravenously active nonpeptide vasopressin-receptor antagonists. Recently, subtype-selective nonpeptide vasopressin-receptor agonists have been developed. A selective V1a-receptor antago- nist, relcovaptan, has shown initial positive results in the treatment of Raynaud’s disease, dysmen- orrhea, and tocolysis. A selective V1b-receptor antagonist, nelivaptan, has beneficial effects in the treatment of psychiatric disorders. Selective V2-receptor antagonists including mozavaptan, lixivaptan, satavaptan, and tolvaptan induce highly hypotonic diuresis without substantially affecting the excretion of electrolytes. A nonselective V1a/V2-receptor antagonist, conivaptan, is used in the treatment for euvolaemic or hypervolemic hyponatremia. Recent basic and clinical studies have shown that AVP-receptor antagonists, especially V2-receptor antagonists, may have therapeutic potential for heart failure. This review presents current information about AVP and its antagonists. Keywords: arginine vasopressin, diuretic, heart failure, vasopressin receptor antagonist 1. Introduction receptor blockers, diuretics, b-adrenoceptor blockers, digitalis glycosides, and inotropic agents (4).
    [Show full text]
  • Assessment of Novel Drugs for Treating Preterm Labour Using a Translational Model
    Assessment of novel drugs for treating preterm labour using a translational model A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2020 Ammar Ahmed Mohammed School of Health Sciences Division of Pharmacy and Optometry 1 Table of contents Table of contents .............................................................................................. 2 List of Figures .................................................................................................................. 9 List of Tables ................................................................................................................. 20 List of abbreviations ..................................................................................................... 22 Publications .................................................................................................................... 27 Abstract .. ....................................................................................................................... 28 Declaration ..................................................................................................................... 29 Acknowledgements ........................................................................................................ 30 Dedication ...................................................................................................................... 32 1 Chapter 1: ...........................................................................................
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Tractocile, Atosiban
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tractocile 6.75 mg/0.9 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless solution without particles. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: regular uterine contractions of at least 30 seconds duration at a rate of 4 per 30 minutes a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50% a gestational age from 24 until 33 completed weeks a normal foetal heart rate 4.2 Posology and method of administration Posology Treatment with Tractocile should be initiated and maintained by a physician experienced in the treatment of pre-term labour. Tractocile is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Tractocile 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Tractocile 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Tractocile 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Tractocile therapy should preferably not exceed 330.75 mg of atosiban.
    [Show full text]
  • Largescale Synthesis of Peptides
    Lars Andersson1 Lennart Blomberg1 Large-Scale Synthesis of Martin Flegel2 Ludek Lepsa2 Peptides Bo Nilsson1 Michael Verlander3 1 PolyPeptide Laboratories (Sweden) AB, Malmo, Sweden 2 PolyPeptide Laboratories SpoL, Prague, Czech Republic 3 PolyPeptide Laboratories, Inc., Torrance, CA, 90503 USA Abstract: Recent advances in the areas of formulation and delivery have rekindled the interest of the pharmaceutical community in peptides as drug candidates, which, in turn, has provided a challenge to the peptide industry to develop efficient methods for the manufacture of relatively complex peptides on scales of up to metric tons per year. This article focuses on chemical synthesis approaches for peptides, and presents an overview of the methods available and in use currently, together with a discussion of scale-up strategies. Examples of the different methods are discussed, together with solutions to some specific problems encountered during scale-up development. Finally, an overview is presented of issues common to all manufacturing methods, i.e., methods used for the large-scale purification and isolation of final bulk products and regulatory considerations to be addressed during scale-up of processes to commercial levels. © 2000 John Wiley & Sons, Inc. Biopoly 55: 227–250, 2000 Keywords: peptide synthesis; peptides as drug candidates; manufacturing; scale-up strategies INTRODUCTION and plants,5 have all combined to increase the avail- ability and lower the cost of producing peptides. For For almost half a century, since du Vigneaud first many years, however, the major obstacle to the suc- presented his pioneering synthesis of oxytocin to the cess of peptides as pharmaceuticals was their lack of world in 1953,1 the pharmaceutical community has oral bioavailability and, therefore, relatively few pep- been excited about the potential of peptides as “Na- tides reached the marketplace as approved drugs.
    [Show full text]
  • Hemmo Pharmaceuticals Private Limited
    Global Supplier of Quality Peptide Products Hemmo Pharmaceuticals Private Limited Corporate Presentation Privileged & Confidential Privileged & Confidential Corporate Overview Privileged & Confidential 2 Company at a glance • Commenced operations in 1966 as a Key Highlights trading house, focusing on Oxytocin amongst other products Amongst the largest Indian peptide manufacturing company • In 1979, ventured into manufacturing of Oxytocin Competent team of 154 people including 6 PhDs, 60+ chemistry graduates/post graduates and 3 engineers • Privately held family owned company Portfolio – Generic APIs, Custom Peptides for Research and Clinical Development and Peptide • Infrastructure Fragments − State of art manufacturing facility in Developed 21 generic products in-house. Navi Mumbai, 5 more in progress − R&D facilities at Thane and Spain − Corporate office at Worli First and the only independent Indian company to have a US FDA approved peptide manufacturing site Privileged & Confidential 3 Transition from a trading house to a research based manufacturing facility Commenced Commenced Investment in State of the Art Opened R& D Expanded operations manufacturing greenfield project facility at Navi Centre in manufacturing as a trading of peptides intended for Mumbai Girona,Spain capacity House regulated markets commissioned R&D center set up in Infrastructure Mumbai 1966 1979 2005 2007 2008 2010 2011 2012 2014 2015 Oxytocin Oxytocin Desmopressin Buserelin Triptorelin Goserelin Linaclotide Glatiramer amongst Gonadorelin Decapeptide Cetrorelix
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • List of Pharamaceutical Peptides Available from ADI
    List of Pharamaceutical Peptides Available from ADI ADI has highly purified research grade/pharma grade pharmaceutical peptides available for small research scale or in bulk (>Kg scale). (See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2704 Catalog# Product Description Catalog# Product Description PP-1000 Abarelix (Acetyl-Ser-Leu-Pro-NH2; MW:1416.06) PP-1410 Growth Hormone-releasing factor, GRF (human) PP-1010 ACTH 1-24 (Adrenocorticotropic Hormone human) Acetate PP-1420 Hexarelin PP-1020 Alarelin Acetate PP-1430 Histrelin Acetate PP-1030 Angiotensin PP-1440 Lepirudin PP-1040 Angiotensin II Acetate PP-1450 Leuprolide PP-1050 Antide Acetate PP-1460 Leuprorelin Acetate PP-1060 Argipressin Acetate PP-1470 Lipopeptide Acetate PP-1070 Argireline Acetate PP-1480 Lypressin PP-1080 Atosiban Acetate PP-1490 Lysipressin Acetate PP-1090 Aviptadil PP-1500 Matrixyl Acetate PP-1100 Bivalirudin Trifluoroacetate PP-1510 Melanotan I, Acetate PP-1110 Buserelin acetate PP-1520 Melanotan II, MT-II, Acetate PP-1120 Copaxone acetate (Glatiramer acetate) PP-1530 Mechano Growth Factor, MGF, TFA PP-1130 Carbetocin acetate PP-1540 Nafarelin Acetate PP-1140 Cetrorelix Acetate PP-1550 Nesiritide Acetate PP-1150 Corticotropin-releasing factor, CRF (human, rat) Acetate PP-1560 Octreotide Acetate PP-1160 Corticotropin-releasing factor, CRF (ovine) PP-1570 Ornipressin Acetate Trifluoroacetate PP-1580 Oxytocin Acetate PP-1170 Deslorelin Acetate PP-1590 Palmitoyl Pentapeptide PP-1180 Desmopressin Acetate PP-1610 Pentagastrin Ammonium
    [Show full text]
  • Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists
    BASIC RESEARCH www.jasn.org Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists Julie Perucca,*† Daniel G. Bichet,‡ Pascale Bardoux,* Nadine Bouby,*† and Lise Bankir*† *INSERM, Unite´ 872, and †UMRS 872, Universite´ Paris Descartes, Centre de Recherche des Cordeliers, Paris, France; and ‡Service de Ne´phrologie, Hoˆpital du Sacre´-Coeur, De´partement de Me´decine, Universite´ de Montre´al, Montre´al, Que´bec, Canada ABSTRACT The mechanisms by which arginine vasopressin (AVP) exerts its antidiuretic and pressor effects, via activation of V2 and V1a receptors, respectively, are relatively well understood, but the possible associated effects on sodium handling are a matter of controversy. In this study, normal conscious Wistar rats were acutely administered various doses of AVP, dDAVP (V2 agonist), furosemide, or the following selective non-peptide receptor antagonists SR121463A (V2 antagonist) or SR49059 (V1a antagonist). Urine flow and sodium excretion rates in the next 6 h were compared with basal values obtained on the previous day, after vehicle treatment, using each rat as its own control. The rate of sodium excretion decreased with V2 agonism and increased with V2 antagonism in a dose-dependent manner. However, for comparable increases in urine flow rate, the V2 antagonist induced a natriuresis 7-fold smaller than did furosemide. Vasopressin reduced sodium excretion at 1 ␮g/kg but increased it at doses Ͼ5 ␮g/kg, an effect that was abolished by the V1a antagonist. Combined V2 and V1a effects of endogenous vasopressin can be predicted to vary largely according to the respective levels of vasopressin in plasma, renal medulla (acting on interstitial cells), and urine (acting on V1a luminal receptors).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
    INN Working Document 18.435 31/05/2018 Addendum1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2013.1 Programme on International Nonproprietary Names (INN) Technologies Standards and Norms (TSN) Regulation of Medicines and other health technologies (RHT) World Health Organization, Geneva © World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme. This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization. Addendum1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1 1 This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2013. ------------------------------------------------------------------------------------------------------------ -apt- aptamers, classical and mirror ones (a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptepid pegol (108), olaptesed pegol (109), pegaptanib (88) (b) -vaptan stem: balovaptan (116), conivaptan
    [Show full text]
  • Salbutamol) in the Treatment of Preterm Labor
    AL-Qadisiya Medical Journal Vol.11 No.20 2015 Effectiveness and safety of the oxytocin antagonist( atosiban) versus beta-adrenergic agonists (salbutamol) in the treatment of preterm labor. Yasamin H. Sharif Al-Shibany* ,Saba M. Swadi Al- Thuwainy * *Obstetrics and Gynecology Department Medical college / Al-Qadisia University ,Email: [email protected] , Email: [email protected] (Received 7 / 4 /2015 , Accepted 19 / 4 / 2015) الخﻻصة : التأثيرات و اﻻعراض الجانبية ﻻستتداا عاتاا اﻻسيستيبا و عتي عاضتد ضﻻتاس لووينيتيستيي الب تر عنتا ضنتتابوت الدةيتتة قالنااانتة ضتتا عاتاا النتتالبييساضي وعتي عاضتتد ضالتي لننتتتابوت البيتتا تت الدةيتة الب تتر ة لعوج حاﻻت اليﻻسة النبكرة. الطر اة: أجر ت الاااسة ضنت لى اليﻻسة و اﻷطلا التعةين الا يانية-العراق , لةلترة ضتي هت ر يتاني الثان /4102 و لغا ة ه ر ياني الثان /4102 ( عةى 011 اضرأة حاضد قعنر 01-52 ستنة( و اسلةتي التى نت الطتياا ضتتا اعتتراض لةتتيﻻسة النبكتترة و يانتتت تتترة الانتتد ضتتي 42-52 أستتبي ( ضتتا وجتتيس انابالتتات لةتترح سنتغرق 51 ثانية قنعا ≤ أاقعة انابالات لو 01 س ياة و يا اسنا عنق الرح ضي 0الى 5 س (و 1التى 5 س (لةنياات عا نة اليﻻسة وسرعة نبض الجنيي طبيعية , س ساني النر ﻻات الى ضجنيعتيي: النجنيعة اﻷولتى و عاسعا 21 ضر ﻻتة عيلجتت قعاتاا النتالبييساضي عتي طر تق ضاةتي الااتي اليا تا و النجنيعتة الثانيتة 21 ضر ﻻة عيلجت قعااااﻻسيسيبا اليا ا ضا ضرا بة هاة اﻻنابالات و اﻻعراض الجانبية لكد عااا عةى اﻻ و الجنيي لغرض سألير اليﻻسة النبكرة و ساةيد النﻻاعلات النر ر ة و الي يات لاى النياليا الداج حا ث اليﻻسة. النتتتا: : لتت كتتي عنتتاف التتتو تت ستتألير حتتاﻻت التتيﻻسة النبكتترة لنتتاة 21 ستتاعة 22% ضااقتتد20%( و 7 أ تتا 41% ضااقتتد 54%( قتتيي النجنيعتتة اﻷولتتى و الثانيتتة عةتتى التتتيال و لكتتي اﻻعتتراض الجانبيتتة ضثتتد سنتتاا نبﻻات ةب اﻻ يانت ايثر عنا النجنيعة اﻷولى الت عيلجت قعاتاا النتالبييساضي 44% ضااقتد 1%(.لت سكتي عناف التو ات النتا: اﻹحصا:ية لةنﻻاعلات النر ر ة لاى النياليا الداج حا ث اليﻻسة قيي النجنيعتيي.
    [Show full text]